Syndax Pharmaceuticals (SNDX) Overweight Rating Maintained at Morgan Stanley; The Target is $24; Panagora Asset Management Has Lifted Diamondback Energy (FANG) Holding

March 14, 2018 - By Adrian Mccoy

Among 9 analysts covering Syndax Pharmac… (SNDX), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Syndax Pharmac… has $40.0 highest and $20 lowest target. $28.83’s average target is 128.81% above currents $12.6 stock price. Syndax Pharmac… had 15 analyst reports since March 28, 2016 according to SRatingsIntel. The stock has “Buy” rating by Citigroup on Monday, March 28. The stock has “Buy” rating by Nomura on Friday, August 11. Oppenheimer maintained it with “Buy” rating and $2900 target in Thursday, August 10 report. The company was initiated on Friday, October 7 by Guggenheim. Morgan Stanley initiated it with “Overweight” rating and $22 target in Monday, March 28 report. Oppenheimer initiated it with “Outperform” rating and $24 target in Thursday, March 31 report. The rating was maintained by FBR Capital on Thursday, January 18 with “Buy”. The stock of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has “Buy” rating given on Tuesday, March 6 by FBR Capital. Citigroup maintained Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) on Friday, August 11 with “Buy” rating. The rating was initiated by JMP Securities with “Market Outperform” on Monday, March 28.

Panagora Asset Management Inc increased Diamondback Energy Inc (FANG) stake by 234.5% reported in 2017Q3 SEC filing. Panagora Asset Management Inc acquired 3,541 shares as Diamondback Energy Inc (FANG)’s stock declined 4.19%. The Panagora Asset Management Inc holds 5,051 shares with $495,000 value, up from 1,510 last quarter. Diamondback Energy Inc now has $12.43B valuation. The stock decreased 0.41% or $0.52 during the last trading session, reaching $126.63. About 286,745 shares traded. Diamondback Energy, Inc. (NASDAQ:FANG) has risen 18.62% since March 14, 2017 and is uptrending. It has outperformed by 1.92% the S&P500.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $307.31 million. The company??s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Analysts await Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to report earnings on May, 14. They expect $-0.94 earnings per share, down 32.39% or $0.23 from last year’s $-0.71 per share. After $-0.80 actual earnings per share reported by Syndax Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 17.50% negative EPS growth.

The stock increased 19.09% or $2.02 during the last trading session, reaching $12.6. About 1.46M shares traded or 314.41% up from the average. Syndax Pharmaceuticals, Inc. (SNDX) has risen 7.09% since March 14, 2017 and is uptrending. It has underperformed by 9.61% the S&P500.

Panagora Asset Management Inc decreased Flagstar Bancorp Inc (NYSE:FBC) stake by 13,344 shares to 291,855 valued at $10.36 million in 2017Q3. It also reduced Icf International Inc (NASDAQ:ICFI) stake by 50,268 shares and now owns 103,810 shares. Procter & Gamble Co/The (NYSE:PG) was reduced too.

Since September 19, 2017, it had 0 insider purchases, and 20 insider sales for $25.19 million activity. Shares for $100,000 were sold by Hollis Michael L.. Pantermuehl Russell sold $387,564 worth of stock. The insider Stice Travis D. sold $10.91M. Soliman Jennifer also sold $23,128 worth of Diamondback Energy, Inc. (NASDAQ:FANG) shares. Another trade for 655 shares valued at $82,678 was sold by Hawkins Thomas F.. On Tuesday, December 12 the insider Van’t Hof Matthew Kaes sold $44,710. 1,000 shares were sold by Dick Teresa L., worth $112,129 on Wednesday, December 13.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: